Nombre del producto:(4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-5-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1λ⁶-benzothiepine-1,1-dione

IUPAC Name:(4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-5-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1λ⁶-benzothiepine-1,1-dione

CAS:197373-42-5
Fórmula molecular:C27H39NO4S
Pureza:95%+
Número de catálogo:CM1046157
Peso molecular:473.67

Unidad de embalaje Stock disponible Precio($) Cantidad

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :197373-42-5
Fórmula molecular:C27H39NO4S
Punto de fusión:-
Código de sonrisas:CCCCC1(CCCC)CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C1=CC=C(OC)C=C1
Densidad:
Número de catálogo:CM1046157
Peso molecular:473.67
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Maralixibat
Mirum announced that the FDA has approved LIVMARLI® (maralixibat) oral solution , ileal bile acid transporter (IBAT) inhibitor for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC). Mirum has also submitted an additional supplemental new drug application (sNDA) to introduce a higher concentration formulation of LIVMARLI, used during the MARCH study, to enable label expansion for younger patients with PFIC, later this year.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.